Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ImageneBio, Inc. (IMA)

ImageneBio names Yanina Grant-Huerta CFO; Chief Medical Officer moves to consulting role

Neutral Impact 4 of 5 leadership Written later

ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer effective July 20, 2026, replacing CEO Kristin Yarema, who had been serving as interim principal financial officer. Separately, Chief Medical Officer Benjamin Porter-Brown will move from a full-time role to a consulting role effective July 24, 2026.

Key points

  • Grant-Huerta receives a $450,000 annual base salary and a 40% target discretionary bonus, plus a 65,000-share RSU grant and a 95,000-share stock option grant.
  • Her severance terms include 12 months of base salary and continued group health benefits for up to 12 months, with enhanced change-in-control benefits.
  • Grant-Huerta previously served as Chief Accounting Officer at Atara Biotherapeutics from March 2025 to July 2026 and spent 14 years at Amgen before that.
  • Dr. Porter-Brown will continue as a consulting clinical development expert and strategic advisor.

The filing

CompanyImageneBio, Inc. (IMA)
Form8-K, current report
Filed with the SECJul 23, 2026, 4:25 PM ET
Accession number0001193125-26-314167

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.